Developmental Therapeutics Program

One Dose Mean Graph

NSC: 768573 / 1	**Conc:** 1.00E-5 Molar	**Test Date:** Nov 26, 2012
Experiment ID: 1211OS83		**Report Date:** Jan 15, 2013

Panel/Cell Line	Growth Percent
Leukemia	
CCRF-CEM	26.51
HL-60(TB)	13.88
K-562	25.07
MOLT-4	-44.96
RPMI-8226	19.70
SR	21.59
Non-Small Cell Lung Cancer	
A549/ATCC	64.62
HOP-62	95.33
HOP-92	56.36
NCI-H226	63.05
NCI-H23	63.19
NCI-H322M	87.21
NCI-H460	51.66
NCI-H522	50.27
Colon Cancer	
COLO 205	101.68
HCT-116	39.31
HCT-15	58.48
HT29	56.23
KM12	46.10
SW-620	73.57
CNS Cancer	
SF-268	64.66
SF-295	47.87
SNB-19	78.19
SNB-75	73.17
U251	63.25
Melanoma	
MALME-3M	90.62
M14	50.02
MDA-MB-435	31.69
SK-MEL-2	89.53
SK-MEL-28	88.83
SK-MEL-5	8.53
UACC-257	86.61
UACC-62	67.78
Ovarian Cancer	
IGROV1	57.49
OVCAR-3	68.92
OVCAR-4	61.55
OVCAR-5	89.80
OVCAR-8	43.19
NCI/ADR-RES	33.11
SK-OV-3	107.50
Renal Cancer	
786-0	64.15
A498	47.73
ACHN	66.87
CAKI-1	62.41
RXF 393	55.83
SN12C	66.08
TK-10	79.74
UO-31	53.43
Prostate Cancer	
PC-3	30.93
DU-145	70.14
Breast Cancer	
MCF7	62.09
MDA-MB-231/ATCC	63.98
HS 578T	55.57
BT-549	20.88
T-47D	26.43
MDA-MB-468	66.85
Mean	56.51
Delta	101.47
Range	152.46

Mean Growth Percent - Growth Percent